CABOMETYX is the only preferred tyrosine kinase inhibitor (TKI) treatment option for first-line patients in the poor- and intermediate-risk groups (Category 2A)
CABOMETYX is a recommended first-line treatment option for favorable-risk patients (Category 2B)
CABOMETYX is the only preferred TKI treatment option for previously treated patients (Category 1)
Exelixis submitted a sNDA for Cabometyx in previously treated advanced HCC in May of 2018
